A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries (SURF)

FrontAce Scientific Co., Ltd

Status: Enrolling

Conditions: Peripheral Arterial Disease; Dissection; Stenosis

Treatments: Device: Sperstent® peripheral spot stent system; Device: Everflex® self-expanding peripheral stent system

Study type: Interventional

Funder types: Industry

Identifiers

NCT06539689

FA001

Details and patient eligibility

About

This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and/or dissections in femoral and proximal popliteal arteries.

Enrollment: 240 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-85 years old, male or female;
• The target lesion is located in the superficial femoral artery or the proximal popliteal artery;
• Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;
• Estimated life expectancy >1 year;
• Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.

Angiographic Inclusion Criteria:

• Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);
• Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);
• After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate);
• Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;
• Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).

Exclusion criteria

• Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;
• Patients with serum creatinine >2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis;
• Severe coagulation disorder;
• Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);
• A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);
• Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;
• Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;
• Systemic infection or uncontrolled infection within the target limb;
• Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;
• Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;
• Patients who are planning to have major lower limb amputations on the target side of the lesion;
• Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;
• Participating in clinical trials of other medical devices or drugs;
• The investigator considers the patient is not suitable for participation in the clinical trial.

Angiographic Exclusion Criteria:

• Failure of the guidewire to pass through the lesion；
• During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy；
• The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation；
• The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification；
• Acute vascular occlusion or acute or subacute thrombosis in the target lesion；
• Stent was implanted into the target vessel before enrollment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

240 participants in 2 patient groups

Sperstent® peripheral spot stent system

Experimental group

Description:

subjects using the Sperstent® peripheral spot stent system

Treatment:

Device: Sperstent® peripheral spot stent system

Everflex® self-expanding peripheral stent system

Active Comparator group

Description:

subjects using the Everflex® self-expanding peripheral stent system

Treatment:

Device: Everflex® self-expanding peripheral stent system